China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SHE:300294)

Market Cap	7.53B -39.4%
Revenue (ttm)	1.69B -8.2%
Net Income	-61.45M
EPS	-0.12
Shares Out	504.25M
PE Ratio	n/a
Forward PE	17.79
Dividend	0.22 (1.49%)
Ex-Dividend Date	May 20, 2026

Volume	7,525,795
Open	14.72
Previous Close	14.34
Day's Range	14.31 - 14.97
52-Week Range	13.64 - 25.64
Beta	0.42
Analysts	Buy
Price Target	28.00 (+87.42%)
Earnings Date	Oct 30, 2026

About SHE:300294

China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the research, development, production, and sale of blood products in China. It offers blood products, such as human serum albumin; human, intravenous, freeze-dried intravenous, hepatitis B, tetanus, and rabies immunoglobulin; and human fibrinogen, prothrombin complex, and coagulation factor VIII. The company also provides compound bone peptide, oxytocin, heparin sodium injection, posterior pituitary, and carboprost tromethamine injection. In addition, it engages in research, devel...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 1,947
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300294

Financial Performance

In 2025, SHE:300294's revenue was 2.06 billion, an increase of 18.69% compared to the previous year's 1.73 billion. Earnings were 112.70 million, a decrease of -71.61%.

Analyst Summary

According to 4 analysts, the average rating for 300294 stock is "Buy." The 12-month stock price target is ¥28.00, which is an increase of 87.42% from the latest price.

Price Target

¥28.00

(87.42% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 2, 2026

Data Sources Report a data error